ObjectiveaaThe core deficit of attention deficit hyperactivity disorder (ADHD) is associated with frontal cortex and related circuitry. Children with ADHD and a medication history have shown atypical brain activation in prefrontal and striatal brain regions during cognitive challenge. We investigated two cognitive control operations such as interference suppression (IS) and response inhibition (RI) in children with ADHD. We also assessed the brain functions affected by the methylphenidate (MPH) effect by comparing the blood-oxygen level dependent (BOLD) signals in ADHD children on and off medication.
Introduction
Attention deficit hyperactivity disorder (ADHD) is the most common developmental disorder of childhood, 1 and its various cognitive and behavioral manifestations can be explained by a deficit in the frontal cortex and related circuitry. 2 Several cognitive models have proposed that reduced response inhibition (RI) is a cardinal symptom of ADHD.
1 Cognitive control, the ability to voluntary constrain actions in a goal-directed manner, comprises at least two operations, RI and interference suppression (IS). Measured by error of commission on cueguided tasks in the inhibition of a prepotent response, RI is reduced in subjects with ADHD. 3, 4 Similarly, IS, which can be measured by erroneous or slower responses to target stimulus due to of interference from competing responses, is also reduced in subjects with ADHD.
Generally, when children grow into adolescences, RI and IS improve 6, 7 in accordance with myelination and synaptic organization, 8, 9 and in accordance with functional activation of the frontal cortex. 10, 11 However, children with ADHD show delayed or abnormal maturation of the frontal cortex and related circuitry leading to inefficient cognitive control behaviors. 4 Methylphenidate (MPH), used as the first line therapy for ADHD patients, is known to significantly improve cognitive control function with respect to RI; however, with only minimal effect on IS. 5 Structural MRI studies have demonstrated abnormally reduced right frontal lobes, 11 as well as similarly affected striatal 12 and cerebellar 13 structures in ADHD subjects. Causal models of ADHD have long implicated dysfunction in the frontostriatal networks supporting executive function, a hypothesis that can be examined systematically using functional neuroimaging. 12, 14 Previous functional imaging studies in the course of the go/no-go have shown abnormalities in frontal lobe activation in children and adolescents with ADHD. 4 Additionally, children with ADHD together with their medication history have shown atypical brain activation in prefrontal and striatal brain regions during cognitive challenge. 15 To the best of our knowledge, few studies have been done in children with ADHD in Korea using fMRI. In this study, we investigated the neural basis of two cognitive control operations, IS and RI, among children with ADHD. We also assessed the brain regions affected by the MPH effect by comparing the blood-oxygen level dependent (BOLD) signals in ADHD children either on or off medication.
Methods

Subjects
This study was conducted in eight right handed ADHD boys (age: 10.3±1.3, elementary school 4-6th grade) who exhibited a good treatment response to MPH. All patients were put into the ADHD category according to DSM-IV 16 and the ADHD Rating Scale-IV (ARS) 17 after interviews with child and adolescent psychiatrist. Diagnoses were confirmed by another psychiatrist according to Kiddie Schedules for Affective Disorder and Schizophrenia-Present and Lifetime version (KSADS-PL).
18 Exclusion criteria were those under an IQ of 85 as per the Wechsler Intelligence Scale for Children (K-WISC-III) test, 19 and those who had history or evidence of neurological disorders or Axis 1 psychiatric disorders. Study objectives and methods were fully explained to recruited patients and parents and verbal assent and written consent were obtained.
If needed, prior to MRI scan, an explanation of the procedures and equipment used in fMRI was provided. Fees for two fMRI scanning were paid by the investigators. This study protocol was approved by the Institutional Review Board (IRB) of Chung Ang University Hospital, South Korea.
Task procedure
The first MRI scan was performed while the patients were medicated, and the second MRI scan was done after the medication had been intentionally discontinued for 1 week as previously suggested by Shafritz et al. 20 and Zang et al. 21 Every attempt was made to maintain general clinical treatment settings. Patients were instructed to take their medication at 8 a.m. and the fMRI was performed at 2 p.m. when the maximum concentration had been attained. Five ADHD patients were taking Concerta ® (27-45 mg) and other three others were taking Metadate CD ® (30-40 mg). Both fMRI scans were performed at the same time of day. The subjects viewed the projected, computer-controlled paradigm on a screen at the head of the scanner via a 45° angled mirror, affixed to the MRI head coil. They used their right hand to hold a button and responded by pressing it with their index and middle fingers. To minimize head movement, memory form fit to each subject was used.
Subjects performed two runs of a modified Eriksen flanker task ( Figure 1) 6 using E-prime (Psychology Software Tools, Pittsburgh, PA, USA). Each trial consisted of a display comprised of a central arrow with two flanking stimuli on either side. Subjects were instructed to press one of two buttons indicating the direction of the central arrow (left/right) while ignoring the flanking stimuli. On congruent and incongruent trials, the flankers were arrows pointing in the same or different directions, respectively in relation to the central arrow. On neutral trials, the flankers were diamonds that were not associated with a response. On no-go trials, the flanking stimuli signals were Xs, indicated that subjects should have withheld their response. Trials were presented in a rapid event-related design 10 with a 3-second intertrial interval. In each trial, the display (800 msec) was followed by a blank screen (300 msec) and then a fixed stimulus (1600 msec); intertrial interval was 300 msec. Subjects practiced about 40 times for about 2 minutes prior to conducting the actual test, which consisted of 252 trials all of which took 12 minutes and 36 seconds.
Imaging procedure
Prior to the MRI scans, a subject's head was fixed and confirmed as to whether the subject could see the screen. A 3-T MRI (Philips Achieva 3.0T X-series) was used to acquire T1-weighted flow compensated spin-echo anatomical images (TR=500 msec; minimum TE) in 16 contiguous 7-mm axial slices, parallel to the plane of the anterior commissure-posterior commissure. Functional acquisition included the same slices with a T2*-sensitive gradient echo spiral pulse sequence with parameters of TR=1,000 msec, TE=30 msec, a field of view=23 cm, a flip angle=90° and an 80×80 matrix.
Data analysis
Using SPM2 (Wellcome Department of Cognitive Neurology, London, UK), images were corrected for differences in slice acquisition time and motion. All subjects displayed less than 1 mm of motion in x, y, and z directions throughout the course of each scan. Images were normalized into a standard space 22 and interpolated to 2×2×2 mm cubic voxels. Normalized image volumes were spatially smoothed (8-mm full width at half-maximum Gaussian kernel) and temporally filtered (low-pass filter: 4-msec Gaussian; high-pass filter: calculated on the basis of trial frequency). fMRI responses were modeled using a canonical hemodynamic response function. For each subject, activation maps were generated using linear contrasts identifying regions that were more active during incongruent relative to neutral trials and during no-go relative to neutral trials. All analyses were generated by using a voxel-level height threshold of p<0.05 uncorrected for multiple comparisons as well as a spatial extent threshold of 30 voxels.
Results
Demographic and clinical characteristics of subjects are shown in Table 1 . The ARS score of subjects at baseline was 36.2±8.3 (inattention 19.8±3.2, hyperactivity-impulsivity 16.3±5.9) and Clinical Global Scale-Severity (CGI-S) was over 4 (4.5±0.8). After three months of treatment, those with CGI-S and CGI-improvement (CGI-I) scores less than 2 were defined as good responders and were included in this study. The ARS score for on-MPH was 20.7±9.5 (inattention 11.3 ±5.7, hyperactivity-impulsivity 9.3±4.3) and that for off-MPH was 28.3±8.2 (inattention 15.0±5.4, hyperactivity-impulsivity 13.3±3.5). There were no significant differences in cognitive data during the modified Eriksen flanker task between on and off MPH, including reaction time of congruent stimuli and accuracy rate on go/no-go tasks. But there was a significant difference in the reaction time of incongruent stimuli between on and off treatment (p=0.01). Average MPH doses during first scan was 34.2±7.5 mg/day for Concerta ® and 36.7±5.8 mg/day for Metadate CD ® . As seen Table 2 and Figure 2 , ADHD children exhibited activation of the right frontal lobe, and in particular, the superi- 
Discussion
This study was an fMRI pilot study conducted in 4-6th grade elementary school children using an event-related design. The authors believe this study to be the first fMRI study conducted in Korean children with ADHD using such a design. From the study results, the suppression of the interfering response was associated with an increased activation of the right frontal lobe in medicated ADHD children. This finding suggested that MPH affected the activation of the right frontal cortex, which correlates with improvement of IS during cognitive challenge.
Vaidya et al. 23 reported that ADHD patients lacked right frontal lobe activation during RI and exhibited decreased activity of the left inferior frontal lobe during IS. Further, Bush et al. 24 reported decreased cingulate cortex activity and atypical fronto-striatal activity during IS in adults with ADHD. Several studies 25, 26 have also reported that ADHD children exhibit relatively decreased fronto-striatal activity compared to other normal children. However, some studies have also reported increased activity or no difference. 4 These controversial findings may stem from differences in the event-related paradigm. In a recent study, Bush et al. 27 reported increases in the activity of the dorsal anterior midcingulate cortex, right dorsolateral prefrontal cortex, and both parietal lobes in adult AD-HD patients on OROS MPH for 6 weeks. Also, during IS, AD-HD patients are known to show atypical activation of the frontal lobe and caudate nucleus when compared to normal control group. 23 In this study, altered activation of the caudate nucleus was not found; however, decreased activity of the frontal lobe was observed when MPH was discontinued as compared to when patients were on MPH. In particular, when subjects were on MPH, greater activation of the frontal lobe was observed during IS than when neutral stimulus was given (Figure 2) . The authors could conclude that MPH has an effect on the right frontal lobe during IS test which corresponds with the results of Bush et al. 27 ; however, changes in the right frontal lobe activity during an RI task with MPH administration were not seen in this study.
Scheres et al. 5 reported that MPH had an affect on response time of RI rather than on IS and that this affect was unrelated to dose. On the other hand, in this study, only response time significantly different between on and off MPH during IS, a finding which is in contrast to previous studies. Further, although medication was discontinued for a week, considering inconsistent cognitive data with previous studies, the residual effect of long term medication treatment cannot be excluded. Finally, a dose-response relationship was not verified in this study.
In the current study, subjects exhibited symptomatic improvements with MPH; however, improved executive function of the frontal lobe was not observed except for the response time of IS. Further, MPH-induced increases in frontal lobe activity were identical to those in previous studies. 23, 28 Several studies 10, 29 have reported that the lateral frontal lobe may be the center for interference control in adults. This study replicated previous study results and suggested the possibility of concluding that MPH can normalize ADHD's cognitive control center. But unlike Bush et al.'s results, 24, 27 decreased activity in the anterior cingulate in adult with ADHD during IS was not observed.
The dopamine system affect on the fronto-sriatal network, as related to the RI model, can be activated by MPH treatment; however, this activated fronto-striatal network alone cannot fully explain improved IS. The role of the parieto-temporal network in IS improvement is also important. 30, 31 Unlike previous studies, 5,32 the effect of MPH related to IS as opposed to RI was observed in this study.
Comprehensive results from the previous fMRI studies using event-related designs on cognitive controls 25, 30, 33 have revealed the activation of widespread regions of the frontal cortex during RI. Particularly striking is the predominance of right-hemisphere activation, especially within the inferior frontal region. Recently, Bush et al. 27 focused on changes in the right frontal lobe activity during IS in adults with ADHD on medication. This study also revealed increased right frontal lobe activity similar to that of healthy children during incongruent stimulus while being treated with MPH.
This study was limited in that it utilized a sample size that was too small to generalize the relationship between MPH and increased activity of the right frontal lobe. Further studies utilizing a larger sample size are needed. Moreover, there was no normal control group for head-to-head comparisons. A second limitation was that subjects were recruited from a population that had been undergoing treatment in clinical practice. That was why the second MRI scan was done one week after discontinuation of medication. However, it was impossible to completely exclude the possibility of a residual effect of longterm medication. Thus in further studies, drug-naïve patients should be selected for such studies and the first MRI should be performed prior to medication initiation and a subsequent MRI can proceed after the initiation of medication.
